U.S. Eliquis Market Size & Outlook, 2025-2033
Related Markets
U.S. eliquis market highlights
- The U.S. eliquis market generated a revenue of USD 5,844.9 million in 2024 and is expected to reach USD 5,443.8 million by 2033.
- The U.S. market is expected to grow at a CAGR of -1.9% from 2025 to 2033.
- In terms of segment, atrial fibrillation (af) was the largest revenue generating indication in 2024.
- Atrial Fibrillation (AF) is the most lucrative indication segment registering the fastest growth during the forecast period.
Eliquis market data book summary
| Market revenue in 2024 | USD 5,844.9 million |
| Market revenue in 2033 | USD 5,443.8 million |
| Growth rate | -1.9% (CAGR from 2025 to 2033) |
| Largest segment | Atrial fibrillation (af) |
| Fastest growing segment | Atrial Fibrillation (AF) |
| Historical data | 2021 - 2023 |
| Base year | 2024 |
| Forecast period | 2025 - 2033 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Atrial Fibrillation (AF), Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Post-Operative VTE Prophylaxis (at-risk cases) |
Other key industry trends
- In terms of revenue, U.S. accounted for 28.2% of the global eliquis market in 2024.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2033.
- In North America, U.S. eliquis market is projected to lead the regional market in terms of revenue in 2033.
- Mexico is the fastest growing regional market in North America and is projected to reach USD 264.8 million by 2033.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Eliquis Market Scope
Eliquis Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Mylan N.V. | View profile | - | - | - |
| F. Hoffmann-La Roche Ltd. | View profile | - | - | - |
| AstraZeneca PLC | View profile | 89900 | 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, United Kingdom, CB2 0AA | https://www.astrazeneca.com |
| Bristol-Myers Squibb Co | View profile | 34100 | Route 206 and Province Line Road, Princeton, New Jersey, NJ, United States, 08543 | https://www.bms.com |
| GSK PLC ADR | View profile | 70200 | 980 Great West Road, Brentford, Middlesex, United Kingdom, TW8 9GS | https://www.gsk.com |
| Sanofi SA | View profile | 87994 | 46, avenue de la Grande Armée, Paris, France, 75017 | https://www.sanofi.com |
| Pfizer Inc | View profile | 88000 | 66 Hudson Boulevard East, New York, NY, United States, 10001-2192 | https://www.pfizer.com |
| Teva Pharmaceutical Industries Ltd | View profile | 37851 | 124 Dvora HaNevi’a Street, Tel Aviv, Israel, 6944020 | https://www.tevapharm.com |
| Novartis AG ADR | View profile | 76057 | Lichtstrasse 35, Basel, Switzerland, 4056 | https://www.novartis.com |
| Johnson & Johnson | View profile | 134400 | One Johnson and Johnson Plaza, New Brunswick, NJ, United States, 08933 | https://www.jnj.com |
U.S. eliquis market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to eliquis market will help companies and investors design strategic landscapes.
Atrial fibrillation (af) was the largest segment with a revenue share of 68.16% in 2024. Horizon Databook has segmented the U.S. eliquis market based on atrial fibrillation (af), deep vein thrombosis (dvt), pulmonary embolism (pe), post-operative vte prophylaxis (at-risk cases) covering the revenue growth of each sub-segment from 2021 to 2033.
The U.S. holds the largest share in the North America Eliquis (apixaban) market owing to strong physician preference for DOACs in stroke prevention and VTE treatment. The country has a large base of patients requiring long-term anticoagulation due to high rates of cardiovascular disease.
Insurance coverage and formulary inclusion have facilitated consistent access to the drug. Real-world data and comparative studies have positioned Eliquis favorably against other anticoagulants. Marketing and educational initiatives by Bristol Myers Squibb and Pfizer sustain brand visibility. The growing elderly population and sedentary lifestyles continue to expand the market scope.
Reasons to subscribe to U.S. eliquis market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of U.S. eliquis market databook
-
Our clientele includes a mix of eliquis market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the U.S. eliquis market , including forecasts for subscribers. This country databook contains high-level insights into U.S. eliquis market from 2021 to 2033, including revenue numbers, major trends, and company profiles.
Partial client list
U.S. eliquis market size, by indication, 2021-2033 (US$M)
U.S. Eliquis Market Outlook Share, 2024 & 2033 (US$M)
Related industry reports
Related statistics
No records
No related statistics found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
